Analyst Undervalued Stocks on the NAS March 2026

March 09, 2026

Analyst Undervalued

Companies on this list are considered undervalued based on the analyst consensus. This means that the average analyst target price is greater than the close price.

NASDAQ

The National Association of Securities Dealers Automated Quotations (Nasdaq) located in New York City, is the most active stock exchange by volume in the United States.

About the Data

This table includes the close price and analyst target price mean from most recent available data. The fiscal year indicates the year for the analyst target price, as the target may not always be for the current year. The number of estimates indicates the number of analyst targets used to calculate the target price mean.

How do you use this table?

Analysts believe that the companies on this list will see the close price move up to their target price mean by the target year indicated. Companies with a large analyst following or large difference between close price and target price are particularly interesting to investigate further. This becomes a starting point for further analysis to understand why these companies are undervalued. Stocks in this category are generally held for capital appreciation or dividends.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

SymbolNameClose PriceTarget Price MeanTarget YearNumber of EstimatesCurrency
TIL Instil Bio Inc. 22.98 125.00 2025 1 USD
APVO Aptevo Therapeutics Inc 1.50 420.00 2025 1 USD
RNAZ Transcode Therapeutics Inc 10.70 280.00 2025 1 USD
QNRX Quoin Pharmaceuticals Ltd DRC 7.41 150.00 2025 3 USD
ALZN Alzamend Neuro Inc 2.35 180.00 2026 1 USD
LYRA Lyra Therapeutics Inc 6.41 100.00 2025 1 USD
CHTR Charter Communications Inc 263.00 456.00 2025 5 USD
COST Costco Wholesale Corp 956.29 1098.00 2026 5 USD
DUOL Duolingo Inc 285.91 500.00 2025 1 USD
EQIX Equinix Inc 780.60 1011.67 2025 3 USD
All data provided as at market close December 13, 2025.

Company Details

Instil Bio Inc.

TIL:NAS

Close Price

22.98

Target Price Mean

125.00

Target Year

2025

Target Price # Estimates

1

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. Its lead products candidate is AXN-2510/IMM2510 that is in Phase 1b/2 clinical trial for the treatment of patients with chemotherapy in patients with advanced/metastatic non-small cell lung cancer.

Access the stockcalc valuation


Aptevo Therapeutics Inc

APVO:NAS

Close Price

1.50

Target Price Mean

420.00

Target Year

2025

Target Price # Estimates

1

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.

Access the stockcalc valuation


Transcode Therapeutics Inc

RNAZ:NAS

Close Price

10.70

Target Price Mean

280.00

Target Year

2025

Target Price # Estimates

1

TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.

Access the stockcalc valuation


Quoin Pharmaceuticals Ltd DRC

QNRX:NAS

Close Price

7.41

Target Price Mean

150.00

Target Year

2025

Target Price # Estimates

3

Quoin Pharmaceuticals, Ltd., a late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). It also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat Netherton Syndrome; and QRX008 for the treatment of scleroderma.

Access the stockcalc valuation


Access our valuation for these companies and 9,000+ more

Try the stockcalc platform free for 30 days

Sign Up

Alzamend Neuro Inc

ALZN:NAS

Close Price

2.35

Target Price Mean

180.00

Target Year

2026

Target Price # Estimates

1

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders.

Access the stockcalc valuation


Lyra Therapeutics Inc

LYRA:NAS

Close Price

6.41

Target Price Mean

100.00

Target Year

2025

Target Price # Estimates

1

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.

Access the stockcalc valuation


Charter Communications Inc

CHTR:NAS

Close Price

263.00

Target Price Mean

456.00

Target Year

2025

Target Price # Estimates

5

Charter Communications, Inc. operates as a broadband connectivity and cable operator company serving residential and commercial customers in the United States.

Access the stockcalc valuation


Costco Wholesale Corp

COST:NAS

Close Price

956.29

Target Price Mean

1098.00

Target Year

2026

Target Price # Estimates

5

Costco Wholesale Corporation, together with its subsidiaries, engages in the operation of membership warehouses in the United States, Puerto Rico, Canada, Mexico, Japan, the United Kingdom, Korea, Australia, Taiwan, China, Spain, France, Iceland, New Zealand, and Sweden.

Access the stockcalc valuation


Duolingo Inc

DUOL:NAS

Close Price

285.91

Target Price Mean

500.00

Target Year

2025

Target Price # Estimates

1

Duolingo, Inc. operates as a mobile learning platform in the United States, the United Kingdom, and internationally. The company offers courses in 40 different languages, including Spanish, English, French, German, Italian, Portuguese, Japanese, and Chinese through its Duolingo app. It also provides a digital English language proficiency assessment exam. The company was incorporated in 2011 and is headquartered in Pittsburgh, Pennsylvania.

Access the stockcalc valuation


Equinix Inc

EQIX:NAS

Close Price

780.60

Target Price Mean

1011.67

Target Year

2025

Target Price # Estimates

3

Equinix, Inc. (Nasdaq: EQIX) shortens the path to boundless connectivity anywhere in the world. Its digital infrastructure, data center footprint and interconnected ecosystems empower innovations that enhance our work, life and planet. Equinix connects economies, countries, organizations and communities, delivering seamless digital experiences and cutting-edge AI quickly, efficiently and everywhere.

Access the stockcalc valuation


Access thousands of valuation reports

Try the stockcalc platform for 30 days for unlimited access to our valuation reports

Sign Up
Instil Bio and Aptevo Therapeutics are among the most undervalued NAS stocks this month. See the most undervalued companies on the blog: https://www.stockcalc.com/Blog/analyst-undervalued-stocks-nas-march-2026
Instil Bio $TIL and Aptevo Therapeutics $APVO on the #NAS among the most undervalued this month. See the full list of undervalued companies: https://www.stockcalc.com/Blog/analyst-undervalued-stocks-nas-march-2026
Instil Bio and Aptevo Therapeutics are among the most undervalued NAS stocks this month. See the most undervalued companies on the blog: https://www.stockcalc.com/Blog/analyst-undervalued-stocks-nas-march-2026

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.